Phase 2 Osteoarthritis Trial, Recruiting NCT06038331 Sponsor: TBF Genie Tissulaire Condition: Osteoarthritis
Back to Osteoarthritis

Phase 2 Osteoarthritis Trial, Recruiting

NCT06038331
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are a man or woman between 18 and 75 years old.
  • You have been diagnosed with a painful condition affecting a specific joint in your wrist called the STT joint (where three small wrist bones meet).
  • You have been receiving medical treatment for your wrist symptoms for more than 3 months with no significant improvement, and surgery has been recommended.
  • Your wrist disability score on a specific questionnaire (QuickDash) is above a certain threshold, indicating a meaningful impact on daily activities.
  • Your wrist pain at rest, measured on a scale of 0 to 10, is rated 4 or higher.
  • You have been given information about the study and have agreed to take part.
  • You are covered by a national health insurance plan.

Who may not be able to join:

  • You are pregnant, breastfeeding, or not using an effective form of contraception (for women).
  • You have a painful condition affecting the joint at the base of your thumb that has not been stabilised or treated (confirm with trial site).
  • You have nerve-related symptoms that affect how you function, such as abnormal or heightened sensitivity to touch or pain.
  • You have epilepsy or a nerve condition that is not well controlled and would make a type of local anaesthetic (locoregional anaesthesia) unsafe for you.
  • You are currently under a court or government order that restricts your freedom.
  • You are under a legal protection order or are unable to give your own consent to participate.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 4 72 68 69 09

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
TBF Genie Tissulaire
Registry
ClinicalTrials.gov
Start date
28 May 2024
Est. completion
1 December 2026

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Decrease of the symptomatology related to the STT OA

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov